Highly selective bradykinin agonists and antagonists with replacement of proline residues by N-methyl-D- and L-phenylalanine

被引:23
作者
Reissmann, S
Schwuchow, C
Seyfarth, L
DeCastro, LFP
Liebmann, C
Paegelow, I
Werner, H
Stewart, JM
机构
[1] UNIV ROSTOCK, INST PHARMACOL & TOXICOL, D-18057 ROSTOCK, GERMANY
[2] UNIV ROSTOCK, INST IMMUNOL, D-18057 ROSTOCK, GERMANY
[3] UNIV COLORADO, SCH MED, DEPT BIOCHEM, DENVER, CO 80262 USA
关键词
D O I
10.1021/jm9301954
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
For further studies on the structural and conformational requirements of positions 2, 3, and 7 in the bradykinin sequence, we replaced the proline residues by the more hydrophobic and conformationally restricted N-methyl-L- and D-phenylalanine (NMF). The biological activities of the new analogs were evaluated on rat uterus, guinea pig ileum, and guinea pig lung strip. Receptor binding of the analogs was studied in membranes from rat uterus and guinea pig ileum. Influence of bradykinin analogs on the release of cytokines from mouse spleen cell cultures was also measured. Bradykinin analogs were synthesized by the solid phase method, using Boc strategy on PAM or Merrifield resins. The best results in the formation of the N-methylamide bond were obtained with the coupling reagent PyBrop. In position 7 the substitution of D-Phe by D-NMF, retaining the configuration of the amino acid, converts bradykinin antagonists into agonists. The bradykinin analogs with D-NMF at position 7 gave the highest known tissue selectivity for rat uterus among agonists. [L-NMF(2)]bradykinin has moderate agonist activity on rat uterus but antagonist activity on guinea pig lung strip. It represents a new antagonist for B-2 receptors without any replacement at position 7. The same analog completely inhibits bradykinin-evoked cytokine expression by mononuclear cells.
引用
收藏
页码:929 / 936
页数:8
相关论文
共 57 条
[1]  
BHOOLA KD, 1992, PHARMACOL REV, V44, P1
[2]   SYNTHESE DE LA L-ARGINYL-L-PROLYL-L-PROLYL-GLYCYL-L-PHENYLALANYL-L-SERYL-L-PROLYL-L-PHENYLALANYL-L-ARGININE, UN NONAPEPTIDE PRESENTANT LES PROPRIETES DE LA BRADYKININE [J].
BOISSONNAS, RA ;
GUTTMANN, S ;
JAQUENOUD, PA .
HELVETICA CHIMICA ACTA, 1960, 43 (05) :1349-1358
[3]   RECENT DEVELOPMENTS IN THE UNDERSTANDING OF BRADYKININ RECEPTORS [J].
BURCH, RM ;
KYLE, DJ .
LIFE SCIENCES, 1992, 50 (12) :829-838
[4]  
CHATURVEDI S, 1993, J MED CHEM, V36, P2569
[5]   EVIDENCE FOR A ROLE OF BRADYKININ IN EXPERIMENTAL PAIN MODELS [J].
CHAU, TT ;
LEWIN, AC ;
WALTER, TL ;
CARLSON, RP ;
WEICHMAN, BM .
AGENTS AND ACTIONS, 1991, 34 (1-2) :235-238
[6]   A NEW CLASS OF BRADYKININ ANTAGONISTS - SYNTHESIS AND INVITRO ACTIVITY OF BISSUCCINIMIDOALKANE PEPTIDE DIMERS [J].
CHERONIS, JC ;
WHALLEY, ET ;
NGUYEN, KT ;
EUBANKS, SR ;
ALLEN, LG ;
DUGGAN, MJ ;
LOY, SD ;
BONHAM, KA ;
BLODGETT, JK .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (09) :1563-1572
[7]  
CORNISHBOWDEN A, 1984, EUR J BIOCHEM, V138, P9, DOI 10.1111/j.1432-1033.1984.tb07877.x
[8]   BRADYKININ AND INFLAMMATORY PAIN [J].
DRAY, A ;
PERKINS, M .
TRENDS IN NEUROSCIENCES, 1993, 16 (03) :99-104
[9]  
FARMER SG, 1989, MOL PHARMACOL, V36, P1
[10]  
FARMER SG, 1989, J PHARMACOL EXP THER, V248, P677